Introduction
============

Diabetic neuropathy (DN) is the most common and troublesome complication of diabetes, characterized by the gradual loss of peripheral axons, resulting in diminished sensation, pain, and eventual complete loss of sensation ([@b1-etm-0-0-7441]). Pathologically, it is the culprit of a series of interrelated metabolic abnormalities with insulin deficiency and hyperglycemia ([@b2-etm-0-0-7441]). Importantly, DN affects up to 60--70% of diabetics, leading to the highest morbidity and mortality rates and to a huge economic burden of diabetes care ([@b3-etm-0-0-7441],[@b4-etm-0-0-7441]). However, in addition to controlling blood glucose levels, no effective treatment options have been found to prevent, slow or reverse the progression of DN and are not always achievable even in alert patients ([@b5-etm-0-0-7441]). Besides, a good understanding of pathological and molecular mechanism underlying DN might give help to explore effective therapy of this complicated disease.

The difference of gene expression levels could reflect the propensity of many diseases, and thus identifying gene functions has been an effective way to reveal the pathological mechanism of a disease at molecular level ([@b6-etm-0-0-7441]). ELAVL3, as a member of the Elavl family, is known as a neuronal Elavl because it is expressed in peripheral and central neurons throughout development ([@b7-etm-0-0-7441]). Ogawa *et al* hold the view that ELAVL3 is essential for maintaining Purkinje neuron axons ([@b8-etm-0-0-7441]). It has been reported that ELAVL3 regulates neuronal polarity via alternative splicing of embryo-specific exon in AnkyrinG ([@b9-etm-0-0-7441]). There is some evidence to suggest that Molecule Interacting with CasL-Like1 (MICALL1), involved in pre-cytokinetic events, acts as a membrane hub on tubular recycling endosomes ([@b10-etm-0-0-7441]). According to recent reports, tubular recirculating endosome biogenesis was regulated through p53-MICALL1 pathway ([@b11-etm-0-0-7441]). HEY2, as a member of hairy-related basic helix-loop-helix transcription factor subfamily, is involved in boundary formation and cell fate determination ([@b12-etm-0-0-7441]). Recent research has indicated that miR-98 activated the Notch signaling pathway by binding to HEY2 in Alzheimer\'s disease mice to improve mitochondrial dysfunction and oxidative stress ([@b13-etm-0-0-7441]). Our research results agree with previous studies, suggesting that ELAVL3, MICALL1, HEY2 genes have effects on neurological diseases. It has been demonstrated that by using variants based on the guilty susceptibility (GBA) algorithm, gene function prediction can be performed with very high statistical confidence assuming that the associations in the genetic data is necessary to establish culpability ([@b14-etm-0-0-7441]). Although various of techniques have been proposed for purpose of extending the GBA to indirect connections, only slight effectiveness has been discovered ([@b15-etm-0-0-7441]--[@b18-etm-0-0-7441]).

In the present study, a new method was proposed to predict seed gene functions for progressive DN (PDN) patients, by integrating the GBA algorithm and network-based method. To achieve this goal, gene expression data and gene ontology (GO) annotations were collected from the public databases. Differentially expressed genes (DEGs) were identified as gene lists and background GO terms were extracted as gene sets. The co-expression matrix (CEM) was constructed on gene lists by Spearman correlation coefficient (SCC) method.

Materials and methods
=====================

### Preparing gene expression data

Gene expression data \[GSE24290 ([@b19-etm-0-0-7441])\] for human DN were recruited from the public-free Gene Expression Omnibus (GEO). In brief, based on the density of myelinated fibers, GSE24290 divided the DN patient samples into two groups, progressors and non-progressors. In short, the patients in the progressive group lost ≥500 fibres/mm^2^, and the patients in the non-progressive group lost ≤100 fibres/mm^2^ over 52 weeks ([@b20-etm-0-0-7441]). By mapping these preprocessed probes to gene structures, a total of 10,570 genes were identified for PDN for subsequent analysis.

### Collecting gene sets

All human GO annotations were prepared from the Gene Ontology Consortium ([@b21-etm-0-0-7441],[@b22-etm-0-0-7441]). For purpose of making these retained GO terms more correlated to progressors, we took the intersections between DEGs and GO terms. If the number of DEGs for a GO term was smaller than 20, it was removed. Only GO terms including equal or more than 20 DEGs were reserved.

### Identifying DEGs

DEGs between progressors and non-progressors were detected ([@b23-etm-0-0-7441]). The lmFit function implemented in Limma was utilized to perform linear fitting, empirical Bayes statistics and false discovery rate (FDR) calibration of the P-values on the data ([@b24-etm-0-0-7441],[@b25-etm-0-0-7441]). The thresholds for DEGs were set as P\<0.05 and \|log~2~ fold-change\| \>2.

### Constructing CEM

To further investigate the correlations or interactions among DEGs, a CEM for them was constructed based on the SCC algorithm ([@b26-etm-0-0-7441]). If the SCC for a pair of genes was positive, it would indicate a positive linear correlation between the two genes. Similarly, a negative SCC refers to a negative relationship of the gene pair. In addition, the absolute SCC value of an interaction was denoted as its weight value. Furthermore, the higher the weight value across two genes, the stronger the interaction was, especially for 1. Otherwise, the 0 meant that there was no interaction between two genes. As a result, a CEN was constructed according to weight.

### Network-based GBA algorithm

The GBA algorithm was combined with network to predict significant gene functions for progressors. Specifically, for a DEG in the CEM, we chose its adjacent genes to enrich to a GO term. Based on these GO functional annotations, a multi-functionality (MF) score was assigned to each gene *i* in the CEM ([@b14-etm-0-0-7441])

S

(

i

)

=

∑

k

∨

i

∈

G

O

k

1

N

u

m

i

n

k

\*

N

u

m

o

u

t

k

![](etm-17-05-4176-g00.jpg)

of which *Num~ink~* represented the number of genes within GO group *k*, whose weighting had the effect of giving contribution to a GO group; and *Num~outk~* was the number of genes outside GO group *k* in the CEM, whose weighting provided a corresponding weighting to genes not within the GO group. Note that we computed the AUC for evaluating classification performances between progressors and non-progressors. Here, for assessing the predictive power of machine learners in the support vector machine (SVM) model, AUC is an assessment of the accuracy of clinical classification performance ([@b27-etm-0-0-7441]). Most importantly, an AUC of 0.5 represents classification at chance levels, while an AUC of 1.0 represents a perfect classification. Thus we defined GO terms of AUC \>0.6 as seed gene functions for PDN patients in the present report.

Results
=======

### Gene lists

In this report, based on 10,570 genes in GSE24290, we identified 79 DEGs between progressors and non-progressors by Limma package when setting the thresholds as P\<0.05 and \|log~2~ fold-change\| \>2. All DEGs were ranked in ascending order of their P-values ([Table I](#tI-etm-0-0-7441){ref-type="table"}). We found that the most significant DEGs were *ELAVL3* (P=1.87E-02), *MICALL1* (P=2.51E-02), *HEY2* (P=3.42E-02), *PCDHB1* (P=3.69E-02) and *OR2S2* (P=4.81E-02). Importantly, the 79 DEGs were regarded as gene lists for further exploitation.

### Gene sets

In the Gene Ontology Consortium database, there are 19,003 gene sets involved in 18,402 genes. To make these sets with a stable performance and more correlated to progressors, we chose GO terms from 20 to 1,000 in size and then took intersections between the reserved terms with the gene lists. Only gene sets containing intersected DEGs \>20 were left in the subsequent analysis. Hereinafter, we defined the amount of intersected DEGs as the count value of this term. As a result, a total of 40 GO terms were determined ([Table II](#tII-etm-0-0-7441){ref-type="table"}), termed with background GO terms. There were three terms with Count \>60, cellular component (GO:0005575, Count = 71), biological process (GO:0008150, Count = 67), and molecular function (GO:0003674, Count = 66). Furthermore, we calculated the DEGs by expressing the spectral data. According to the GO enrichment analysis, the enrichment of 79 DEGs in background GO terms was obtained ([@b28-etm-0-0-7441]). DEG annotated to a GO term, and if the gene is present in the GO term, the value is 1 (red), otherwise 0 (yellow). Finally, the heatmap was obtained from the heatmap package in the R language to analyze the above enrichment situation ([Fig. 1](#f1-etm-0-0-7441){ref-type="fig"}). The result of this heatmap was in accordance with [Table II](#tII-etm-0-0-7441){ref-type="table"}. Ultimately, the background GO terms were the gene sets used.

### CEM

With an attempt to investigate biological correlations among DEGs, a CEM with 79 nodes and 3,081 interactions were constructed based on the SCC, of which each interaction possessed a weight value to reveal the interacted strength between two genes. The weight distribution for interactions in this CEM showed the characteristic of good adjacent matrix that weights on its diagonal nearly equaled to 1, which suggested that the CEM had a good network scale property. In particular, an edge between *C6orf120* and *PGAP3* had the highest weight of 0.994. Moreover, to further evaluate the activities of genes in interactions of high weights, topological degree centrality analysis was conducted on all nodes in the CEM. The results showed that *C6orf120* connected with 56 adjacent genes and thus had the highest degree. Subsequently, an assortativity coefficient was calculated to assess degree assortative mixing pattern extent. Consequently, the assortativity coefficient for the CEM was 0.829, indicating that the network had perfect assortative mixing patterns.

A sub-network was extracted from the CEM by selecting those interactions with weight \>0.8 and visualized it by Cytoscape software ([Fig. 2](#f2-etm-0-0-7441){ref-type="fig"}). There were 48 nodes and 330 edges in the sub-network. Among these nodes, *PGAP3, C6orf120* and *RBM12B* had higher degree than the others, which suggested their key roles in the PCN patients and inferred that gene functions participated by them might act as critical processes in progressors.

### Seed gene functions

The AUC index was applied to evaluate the classified performance on MF scores between progressors and non-progressors by the 3-fold cross-validation. Generally, if an AUC for a gene or process was \>0.5, it could be used to classify the case group from controls. In this report, the AUC for the 40 gene sets are shown in [Fig. 3](#f3-etm-0-0-7441){ref-type="fig"}. There were 11 GO terms with AUC \>0.5 in total. Thus, 11 of 40 (27.5%) gene sets had a good classification performance between progressors and non-progressors of DN. Among them, 3 with AUC \>0.6 were considered to be seed gene functions in progressors of DN. The seed gene functions were Binding (GO:0005488, AUC=0.668), Molecular function (GO:0003674, AUC=0.654), and Regulation of metabolic process (GO:0019222, AUC=0.636).

Discussion
==========

In the present study, we predicted seed gene functions in PDN patients by using a network-based GBA method, since the network-based approach systematically investigate the molecular complexity of a particular disease ([@b29-etm-0-0-7441]) and identify potential signatures through bio-molecular networks rather than individual genes ([@b30-etm-0-0-7441],[@b31-etm-0-0-7441]). An integration of co-expression network and the GBA algorithm provide a new manner to predict significant gene functions and reveal molecular mechanism underlying PDN.

On the basis of SCC method, a CEM for progressors was constructed on DEGs, and a sub-network of weight \>0.8 was extracted from the CEM. Interestingly, we found that *PGAP3, C6orf120* and *RBM12B* had high degree both in CEM and its sub-network, which indicated their importance in progressors. Taking *RBM12B* as an example, *RBM12B* (RNA binding motif protein 12B) is a protein coding gene that relates to functions of RNA binding, nucleic acid binding and nucleotide binding ([@b32-etm-0-0-7441]). It has been demonstrated that *Rbm12b* and *Rbm3* are mainly down-regulated and highly responsive to systemic hypoxia in mouse developing brain and placenta ([@b33-etm-0-0-7441]). This is the first time the key role of *RBM12B* in human PDN patients was uncovered. In addition, in our study, this gene was enriched in two seed gene functions, Binding and Molecular function. The possible inference was that the dys-regulation of *RBM12B* might disturb the normal functions of binding and lead to brain injury, even lesions of the nervous system.

Particularly, a total of 40 background GO terms were identified as gene sets for the current study. Subsequently, an MF score was assigned to each gene in the specific gene set, and then an AUC for each GO term was produced to assess the prediction performance between progressors and non-progressors. In consequence, 27.5% of all gene sets had a good classified performance with AUC \>0.5. Most significantly, 3 gene sets with AUC \>0.6 were denoted as seed gene functions for PDN, including Binding, Molecular function and Regulation of metabolic process. It is a common phenomenon that a given gene is present in one or more molecular functions (such as *RBM12B* described above), and two or more genes exhibit the same function.

Cameron *et al* reviewed that poor metabolic control was one of microvascular complications correlated to DN ([@b34-etm-0-0-7441]). Thus, it was important to improve the metabolic conditions that led to the pathology underlying peripheral DN, and the metabolic correction modified symptom control and clinical results ([@b35-etm-0-0-7441]). Moreover, metabolic dysfunction in experimental DN due to energy homeostasis and/or oxidative stress is limited to the sciatic nerve ([@b36-etm-0-0-7441]). Above all, we might conclude various metabolic processes play crucial roles in DP, and thus the regulation of metabolic process has become informative in PDN patients.

In summary, we have predicted 3 seed gene functions for progressors of DP compared with non-progressors utilizing network-based GBA algorithm. The findings provide insights to reveal pathological and molecular mechanism underlying PDN. However, the expression data used in this work was recruited from the open access database, and the 3 seed gene functions still need to be validated.
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![Heatmap for gene lists and sets. The ordinate, 79 differentially expressed genes (DEGs), the abscissa the 40 GO terms. Red, the association between the gene and the go term in sample channel. Yellow, no correlation between the gene and the go term in reference channel.](etm-17-05-4176-g01){#f1-etm-0-0-7441}
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###### 

Gene list for progressive diabetic neuropathy (PDN).

  Rank   DEG            P-value       Rank   DEG        P-value
  ------ -------------- ------------- ------ ---------- -------------
  1      ELAVL3         0.018730149   41     FER1L4     0.237218317
  2      MICALL1        0.025064168   42     TAS2R13    0.254492341
  3      HEY2           0.034183011   43     SYN1       0.254519864
  4      PCDHB1         0.036938421   44     KCNMB4     0.257387331
  5      OR2S2          0.048112652   45     SLC35E1    0.258472445
  6      CNTD2          0.055977842   46     PRX        0.267184163
  7      DNAJB12        0.059213903   47     GIPC2      0.276805505
  8      GPR21          0.061091712   48     RBM12B     0.298659702
  9      PFN1           0.068351436   49     HACD1      0.302339336
  10     ZMIZ2          0.073944462   50     NAALAD2    0.309726354
  11     HSPA6          0.080467794   51     KLHL21     0.310864132
  12     TRIM36         0.082922925   52     TMX2       0.316649651
  13     MTHFD1         0.08313726    53     HEBP2      0.319262815
  14     RPA4           0.091277628   54     RFC2       0.319345713
  15     NIPAL2         0.101024558   55     CCDC134    0.327623954
  16     HDDC2          0.106181304   56     MEPE       0.343481838
  17     LIME1          0.107101383   57     TRAPPC9    0.374991751
  18     MAPKAPK5-AS1   0.108867691   58     TXNRD1     0.384530053
  19     CCDC186        0.116573636   59     CTDNEP1    0.386873156
  20     FCF1           0.117569875   60     SH2D4A     0.39096557
  21     PSMD5          0.118641952   61     ZNF512B    0.390996512
  22     YTHDF3         0.130853807   62     TAGLN2     0.400497742
  23     CDHR5          0.135952991   63     C10orf76   0.401347031
  24     C6orf120       0.1416115     64     PIK3IP1    0.409666004
  25     VWA7           0.144178178   65     C5orf30    0.420802441
  26     ASF1A          0.147208457   66     PKNOX1     0.449555958
  27     NELL2          0.162233252   67     DNAJB2     0.465398033
  28     SRM            0.167545586   68     NCR2       0.474076273
  29     SH3KBP1        0.176459493   69     GALNT8     0.475841943
  30     USE1           0.178993287   70     IKZF3      0.480703371
  31     INSIG1         0.179397171   71     SENP5      0.492341515
  32     SSH3           0.18328187    72     POMGNT2    0.510089318
  33     FAM66D         0.185333874   73     CALHM2     0.515258516
  34     PGAP3          0.190879424   74     ATP8B4     0.5305693
  35     PER2           0.192655455   75     GALNT10    0.543825962
  36     CCS            0.193106321   76     WIZ        0.550465591
  37     E2F8           0.200074614   77     FER        0.594006462
  38     HTR1F          0.221840324   78     PITPNA     0.597706177
  39     ZNF142         0.232301069   79     MYO3A      0.599378182
  40     PPP1R3B        0.236879137                     

###### 

Gene sets for progressive diabetic neuropathy (PDN).

  GO ID        GO term                                    Counts   GO ID        GO term                                    Counts
  ------------ ------------------------------------------ -------- ------------ ------------------------------------------ --------
  GO:0005575   Cellular component                         71       GO:0008152   Metabolic process                          36
  GO:0008150   Biological process                         67       GO:0071704   Organic substance metabolic process        34
  GO:0003674   Molecular function                         66       GO:0016020   Membrane                                   33
  GO:0005623   Cell                                       58       GO:0044237   Cellular metabolic process                 33
  GO:0044464   Cell part                                  58       GO:0044238   Primary metabolic process                  33
  GO:0009987   Cellular process                           57       GO:0043170   Macromolecule metabolic process            28
  GO:0005488   Binding                                    55       GO:0044425   Membrane part                              27
  GO:0044699   Single-organism process                    52       GO:0044444   Cytoplasmic part                           27
  GO:0043226   Organelle                                  49       GO:0044260   Cellular macromolecule metabolic process   26
  GO:0044763   Single-organism cellular process           49       GO:0005634   Nucleus                                    25
  GO:0005622   Intracellular                              47       GO:0016021   Integral component of membrane             25
  GO:0044424   Intracellular part                         47       GO:0031224   Intrinsic component of membrane            25
  GO:0043227   Membrane-bounded organelle                 46       GO:0043167   Ion binding                                24
  GO:0065007   Biological regulation                      43       GO:0050896   Response to stimulus                       24
  GO:0043229   Intracellular organelle                    42       GO:0044422   Organelle part                             23
  GO:0005515   Protein binding                            41       GO:0097159   Organic cyclic compound binding            23
  GO:0043231   Intracellular membrane-bounded organelle   40       GO:1901363   Heterocyclic compound binding              23
  GO:0050789   Regulation of biological process           39       GO:0044446   Intracellular organelle part               22
  GO:0005737   Cytoplasm                                  38       GO:0019222   Regulation of metabolic process            21
  GO:0050794   Regulation of cellular process             37       GO:0032502   Developmental process                      21
